At the end of what was arguably one of the best years for the stock market in more than a decade, investors in any of the 20 top-performing mutual funds of 2024 would have earned a return that nearly ...
A new year means a new Fierce Biotech Fundraising Tracker to record the significant amounts of venture capital being funneled into the industry. We're maintaining the criteria we used for last year's ...
Morningstar’s new Medalist Ratings deliver independent, bottom-up assessments for semiliquid funds—offering transparency in a segment that sits between mutual funds and private markets. Our launch ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results